08

December 8, 2017

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Desipramine, Evodiamine, Atorvastatin, Hypericin, Salinomycin and Temozolomide (DEAHSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 8/December/2017, 10.24 pm

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer […]
December 8, 2017

Combinatorial therapy for Deafness: a therapeutic mix encompassing N-Acetyl Serotonin, Cholecalciferol, Ajoene and DIM (NACAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 8/December/2017, 12.33 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Combinatorial therapy for Deafness: a therapeutic mix encompassing N-Acetyl Serotonin, Cholecalciferol, Ajoene and DIM (NACAD)  increases the expression […]
December 8, 2017

Natural product-based therapy for body weight control, energy homeostasis and TIIDM: Epigallocatechin-3-0-gallate, isolated from Green tea,  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/December/2017, 12.25pm

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
December 8, 2017

Molecular therapy for Diabetic nephropathy (DN): 14,15-Epoxyeicosatrienoic acid increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 8/December/2017, 12.18 pm

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the […]